<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097110</url>
  </required_header>
  <id_info>
    <org_study_id>GN 05</org_study_id>
    <secondary_id>U01HD040565</secondary_id>
    <nct_id>NCT00097110</nct_id>
  </id_info>
  <brief_title>RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil</brief_title>
  <official_title>RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Global Network for Women's and Children's Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Global Network for Women's and Children's Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>John E. Fogarty International Center (FIC)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Federal de Pernambuco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feculdade de Medicina da Universidade de Sao Paulo - Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Global Network for Women's and Children's Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The perinatal morbidity and mortality rates for Brazil are five to ten-fold higher than those
      reported for upper income countries. This study tests the likelihood that the joint
      administration of antioxidants vitamin C (1000 mg) and vitamin E (400 IU) will reduce the
      incidence of preeclampsia among chronically hypertensive pregnant patients and patients with
      a past history of preeclampsia/eclampsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maternal, perinatal and neonatal morbidity and mortality rates for Brazil are five to
      ten-fold higher than those reported for upper income countries. In Sao Paulo, 22 percent of
      maternal deaths are attributable to hypertensive complications of pregnancy, which ranks as
      the number one cause of maternal death. Recent advances in the understanding of the
      pathophysiology of preeclampsia suggest the possibility of antioxidant therapy for the
      prevention of preeclampsia. The primary hypothesis is that the joint administration of the
      antioxidants vitamin C (1000 mg) and vitamin E (400 IU) will reduce the incidence of
      preeclampsia among chronically hypertensive pregnant patients and patients with a past
      history of preeclampsia/eclampsia. Secondary outcomes include severity of preeclampsia;
      incidence of gestational hypertension; incidence of premature rupture of the membranes;
      incidence of preterm birth; incidence of low birth weight infants; biomarker level
      correlation with preeclampsia.

      Study sites are high-risk obstetrical clinics in the Brazilian cities of Recife, Botucatu,
      Campinas, and Porto Alegre. The sample size was based on an estimated risk of
      preeclampsia/eclampsia of 21-25% in the control group. The study hypothesizes a 40% absolute
      reduction of risk of preeclampsia; early treatment withdrawal of 3%; withdrawal of consent or
      loss to follow-up of 10%; calculated at a 0.05 significance level with 80% power. Seven
      hundred thirty-four obstetric patients with chronic hypertension or preeclampsia in the prior
      pregnancy presenting for care between 12 weeks and 19 weeks', 6 days gestation will be
      randomized to a double-blinded placebo controlled trial to receive a daily dose of either
      vitamin E (400 International Units) and vitamin C (1000 mg) or placebo from the time of
      enrollment to delivery. The use of MEMS caps enables researchers to accurately track
      compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of preeclampsia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of preeclampsia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gestational hypertension or preeclampsia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of abruptio placentae</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of preterm birth</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of small for gestational age</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of low birth weight infants</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker level correlation with preeclampsia</measure>
  </secondary_outcome>
  <enrollment>734</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Eclampsia</condition>
  <condition>HELLP Syndrome</condition>
  <condition>Pregnancy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C and E</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age between 12 weeks and 19 weeks, 6 days, inclusive

          -  Chronic hypertension

          -  History of preeclampsia/eclampsia

          -  Attendance at a participating hospital (Recife, Botucatu, Campinas and Porto Alegre,
             Brazil)

        Exclusion Criteria:

          -  Planned delivery elsewhere.

          -  Multifetal gestation.

          -  Allergy to vitamin C or vitamin E.

          -  Requirement for aspirin or anticoagulant medication.

          -  Proteinuria ≥ 2+ on dipstick urine test; or proteinuria = 1+ on dipstick and ≥ 300
             mg/24 hours.

          -  Pre-pregnancy diabetes mellitus.

          -  Known fetal anomaly incompatible with life.

          -  Prior participation in the study.

          -  Unwillingness to take the study medication.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A. Spinnato, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Pernambuco</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://gn.rti.org</url>
    <description>Global Network for Women's and Children's Health Research</description>
  </link>
  <link>
    <url>http://www.rti.org/</url>
    <description>RTI International</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2004</study_first_submitted>
  <study_first_submitted_qc>November 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2004</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Global Network</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Low birth weight infants</keyword>
  <keyword>Brazil</keyword>
  <keyword>Brasil</keyword>
  <keyword>Maternal and child health</keyword>
  <keyword>International</keyword>
  <keyword>Women's health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

